Study: Combo Promising for Metastatic AIPC
SAN FRANCISCO—Adding thalidomide and bevacizumab to docetaxel may hold promise for treating patients with metastatic androgen-independent prostate cancer (AIPC), investigators report.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.